【摘要】 目的 探究替普瑞酮辅助奥美拉唑以及莫沙必利对反流性食管炎(RE)患者的临床治疗效果。方法 选取了2017年1月至2018年11月在我院消化内科就诊的106例RE患者，随机分为对照组和观察组，各53例。对照组患者给予奥美拉唑肠溶胶囊和枸橼酸莫沙必利片，观察组患者则在此基础上加用替普瑞酮胶囊。两组均治疗8周。比较两组患者治疗前后的表皮生长因子(EGF)和环氧合酶-2(COX-2)水平、症状消失时间、胃镜检查正常时间、症状积分、胃镜积分以及生活质量评分。结果 治疗8周后，对照组患者与治疗前比较，EGF水平降低(P<0.05),与治疗4周后比较，EGF水平升高，但差异无统计学意义(P>0.05)。观察组患者治疗8周后与治疗前比较，EGF水平升高，且治疗8周后与治疗4周后，观察组患者的EGF水平均高于对照组(P<0.05)。治疗8周后与治疗前比较，两组患者COX-2水平均降低，且观察组患者的COX-2水平低于对照组(P<0.05)。观察组的症状消失时间及胃镜检查正常时间均短于对照组(P<0.05)。治疗8周后与治疗前比较，两组患者的症状积分和胃镜积分均低于治疗前，而生活质量评分高于治疗前，且观察组患者的症状积分和胃镜积分均低于对照组，而生活质量评分高于对照组(P<0.05)。结论 替普瑞酮辅助奥美拉唑以及莫沙必利对RE患者具有较好的临床治疗效果，可有效改善EGF和COX-2的水平，缓解患者临床症状。更多还原

【Abstract】 Objective To explore the clinical efficacy of teprenone-assisted omeprazole and mosapride in the treatment of reflux esophagitis(RE).Methods Totally 106 patients with RE receiving treatment in our hospital from January 2017 to November 2018 were randomly divided into control group(n=53) and observation group(n=53).Omeprazole enteric-coated capsules and mosapride citrate tablets were given to both groups, while teprenone capsules were added in observation group.Both groups were treated for 8 weeks.The levels of epidermal growth factor(EGF) and cyclooxygenase-2(COX-2),time of symptoms disappearance, time of gastroscopy being, the scores of symptoms, gastroscopy score and quality of life were observed and compared between the two groups.Results Compared with the pre-treatment, the level of EGF in control group decreased 8 weeks after treatment(P<0.05).Compared with 4 weeks after treatment, the level of EGF increased slightly at 8 weeks after treatment, but there was no significant difference(P> 0.05).At 8 weeks after treatment, the level of EGF in observation group was higher than that before treatment, and the level of EGF in observation group was higher than that in control group at 8 weeks and 4 weeks after treatment(P<0.05).At 8 weeks after treatment, the level of COX-2 in both groups decreased, and the level of COX-2 in observation group was lower than that in control group(P<0.05).The time of symptoms disappearance and the time of gastroscopy normal in observation group were lower than those in control group(P<0.05).At 8 weeks after treatment, the scores of symptoms and gastroscopy in two groups were lower than those before treatment, while the score of quality of life was higher than that before treatment.The scores of symptoms and gastroscopy in the observation group were lower than those in control group, while the score of quality of life was higher than that in control group(P<0.05).Conclusion Teprenone-assisted omeprazole and mosapride have good clinical therapeutic effect on patients with RE.It can effectively improve the levels of EGF and COX-2 and alleviate the clinical symptoms of patients.更多还原